All In Biotech

Drug Trial Radar · NCT02071459

Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA

Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo

Last checked: Nov 20, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 107 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

107

Actual

Start

Jan 21, 2014

Primary completion

Oct 28, 2019

Study completion Oct 28, 2019

Sponsor

Lead sponsor
University Hospital, ToulouseAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 25, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the effects of L-Threo DOPS on orthostatic hypotension symptoms and other non-motor symptoms in patients with Multiple System Atrophy (MSA) after 12 weeks following randomization to continued therapy with droxidopa or placebo.

Conditions

  • Multiple System Atrophy

Interventions

  • L-Threo DOPSDrug

    initial dose titration period (4 weeks) followed by 8 weeks at the max tolerated dose

  • placeboDrug

    initial period (4 weeks) followed by 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the efficacy of long term efficacy of L-threo DOPSTime frame: 12 weeks

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Centre hospitalier d'Angers

    Angers, France

  • CHU bordeaux

    Bordeaux, France

  • CHU de Clermont-Ferrand

    Clermont-Ferrand, France

  • CHU de Dijon

    Dijon, France

  • CHRU de lille

    Lille, France

  • CHU de limoges

    Limoges, France

  • Hôpital La Timone

    Marseille, France

  • Hôpital G. & R. Laennec

    Nantes, France

  • Hôpital Pitié-Salpétrière

    Paris, France

  • CHU de Poitiers

    Poitiers, France

  • CHU Pontchaillou

    Rennes, France

  • CHU de Rouen

    Rouen, France

  • chu de Strasbourg

    Strasbourg, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.